Carotid MR Angiography: Phase II Study of Safety and Efficacy for MS-325
Authors:
- David A. BluemkeDBDavid A. Bluemke
- Arthur E. StillmanASArthur E. Stillman
- Kostaki G. BisKBKostaki G. Bis
- Thomas M. GristTGThomas M. Grist
- Richard A. BaumRBRichard A. Baum
- Robert D’aGostinoRDRobert D’aGostino
- Eric S. MaldenEMEric S. Malden
- Joseph A. PierroJPJoseph A. Pierro
- E. Kent YucelEYE. Kent Yucel
- 1 April 2001
- journal article
- clinical trial
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 219 (1) , 114-122
Abstract
To evaluate the safety and efficacy of MS-325 in patients suspected of having carotid arterial disease. Fifty carotid arteries in 26 patients were imaged with three-dimensional spoiled gradient-recalled-echo magnetic resonance (MR) angiography at 5 and 50 minutes after injection of MS-325. MS-325 was administered intravenously as a single dose of 0.01, 0.03, or 0.05 mmol per kilogram of body weight as determined with a dose randomization scheme for four, nine, and 13 patients, respectively. Safety, including clinical laboratory changes and electrocardiographic monitoring, was assessed until approximately 3 days after injection. Conventional contrast agent-enhanced angiography was used as the standard of reference. Independent readers blinded to the dose interpreted the MR angiographic and conventional images. Images were assessed for location and extent of carotid arterial stenosis. There were no severe or serious adverse events. For the determination of clinically significant stenosis (>70%) on the 5-minute images, sensitivity, specificity, and accuracy (P =.07, three-way comparison) were 100%, 100%, and 100%; 63%, 100%, and 88%; and 40%, 75%, and 55% at 0.01, 0.03, and 0.05 mmol/kg, respectively. Sensitivity and specificity for images at 50 minutes after MS-325 administration showed the same trends as the 5-minute images. Overall accuracy for MS-325-enhanced carotid MR angiography performed during steady-state conditions of circulating contrast agent approximately 5 minutes after injection was high (88%-100%) at 0.03 and 0.01 mmol/kg. MS-325 was well tolerated at all evaluated doses.Keywords
This publication has 29 references indexed in Scilit:
- Contrast-enhanced 3D MR DSA of the carotid artery bifurcation: preliminary study of comparison with unenhanced 2D and 3D time-of-flight MR angiography.Radiology, 1998
- Steady-state and dynamic MR angiography with MS-325: initial experience in humans.Radiology, 1998
- Preclinical Evaluation of the Pharmacokinetics, Biodistribution, and Elimination of MS-325, a Blood Pool Agent for Magnetic Resonance ImagingInvestigative Radiology, 1997
- Improved 2D time-of-flight angiography using a radial-linek-space acquisitionMagnetic Resonance in Medicine, 1997
- MS-325: A small-molecule vascular imaging agent for magnetic resonance imagingAcademic Radiology, 1996
- MR angiography in neurologic disease.Radiology, 1994
- Dynamic gadolinium‐enhanced three‐dimensional abdominal MR arteriographyJournal of Magnetic Resonance Imaging, 1993
- Mechanisms of flow‐induced signal loss in MR angiographyJournal of Magnetic Resonance Imaging, 1992
- Volume MR angiography: methods to achieve very short echo times.Radiology, 1990
- MR Angiography with Gradient Motion RefocusingJournal of Computer Assisted Tomography, 1988